LSE:OBI (Canada)
Â
Common Share
ÂŁ
0.14
-0.0050 (-3.57%)
Jul 21
Business Description
Ondine Biomedical Inc
NAICS : 541710
SIC : 3741
ISIN : CA68234M2058
Share Class Description:
LSE:OBI: Common ShareTotal Employee Number:
8,000Description
Ondine Biomedical Inc is a life sciences company, focusing on the development of photodisinfection-based therapies to provide solutions to drug-resistant infections. The company has created a platform technology called antimicrobial photodynamic disinfection, or photodisinfection, to help prevent and help treat infections across different therapeutic areas in healthcare and industry settings. Canada is the major revenue generator for the group. The company has one reportable operating segment that is antimicrobial photodynamic therapy (aPDT) products.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 25.54 | |||||
Equity-to-Asset | 0.24 | |||||
Debt-to-Equity | 0.12 | |||||
Debt-to-EBITDA | -0.01 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -29.91 | |||||
Beneish M-Score | -4.37 | |||||
WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 14.5 | |||||
3-Year EBITDA Growth Rate | 16.8 | |||||
3-Year EPS without NRI Growth Rate | 16.2 | |||||
3-Year FCF Growth Rate | 18.6 | |||||
3-Year Book Growth Rate | -51.9 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 26.85 | |||||
9-Day RSI | 31.24 | |||||
14-Day RSI | 36.83 | |||||
3-1 Month Momentum % | 26.09 | |||||
6-1 Month Momentum % | 81.25 | |||||
12-1 Month Momentum % | 9.43 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.23 | |||||
Quick Ratio | 1.06 | |||||
Cash Ratio | 0.98 | |||||
Days Inventory | 523.67 | |||||
Days Sales Outstanding | 55.13 | |||||
Days Payable | 477.09 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -38.6 | |||||
Shareholder Yield % | -20.22 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 60.91 | |||||
Operating Margin % | -1132.8 | |||||
Net Margin % | -1115.73 | |||||
EBITDA Margin % | -1092.59 | |||||
FCF Margin % | -905.8 | |||||
OCF Margin % | -901.4 | |||||
ROE % | -785.19 | |||||
ROA % | -243.85 | |||||
ROIC % | -534.5 | |||||
3-Year ROIIC % | -161.64 | |||||
ROC (Joel Greenblatt) % | -3064 | |||||
ROCE % | -760.88 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 45 | |||||
PB Ratio | 33.75 | |||||
EV-to-EBIT | -4.06 | |||||
EV-to-EBITDA | -4.15 | |||||
EV-to-Revenue | 45.29 | |||||
EV-to-Forward-Revenue | 22.3 | |||||
EV-to-FCF | -5 | |||||
Price-to-GF-Value | 1.35 | |||||
Earnings Yield (Greenblatt) % | -24.63 | |||||
FCF Yield % | -18.47 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Ondine Biomedical Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ÂŁ) | 1.43 | ||
| EPS (TTM) (ÂŁ) | -0.032 | ||
| Beta | -0.1593 | ||
| 3-Year Sharpe Ratio | 0.39 | ||
| 3-Year Sortino Ratio | 0.66 | ||
| Volatility % | 50.52 | ||
| 14-Day RSI | 36.83 | ||
| 14-Day ATR (ÂŁ) | 0.006825 | ||
| 20-Day SMA (ÂŁ) | 0.144475 | ||
| 12-1 Month Momentum % | 9.43 | ||
| 52-Week Range (ÂŁ) | 0.075 - 0.185 | ||
| Shares Outstanding (Mil) | 519.55 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Ondine Biomedical Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Ondine Biomedical Inc Stock Events
| Event | Date | Price (ÂŁ) | ||
|---|---|---|---|---|
| Second quarter earnings conference call for 2026 | 2026-09-25 15:30 | In 66 days | ||
| Second quarter earnings results for 2026 | 2026-09-25 | In 65 days | ||
| General meeting for 2026 | 2026-06-30 08:00 | 0.15 (+0.00%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-06-04 15:30 | 0.15 (-3.33%) | ||
| Annual report for 2025 | 2026-06-04 | 0.15 (-3.33%) | ||
| Fourth quarter earnings results for 2025 | 2026-06-04 | 0.15 (-3.33%) | ||
| Second quarter earnings conference call for 2025 | 2025-09-26 15:30 | 0.15 (+1.75%) | ||
| Second quarter earnings results for 2025 | 2025-09-26 | 0.15 (+1.75%) | ||
| General meeting for 2025 | 2025-06-26 16:00 | 0.14 (+1.79%) | ||
| Fourth quarter earnings conference call for 2024 | 2025-05-15 16:30 | 0.09 (+0.00%) |
Show
Entries
Ondine Biomedical Inc Frequently Asked Questions
What is Ondine Biomedical Inc(LSE:OBI)'s stock price today?
The current price of LSE:OBI is ÂŁ0.14. The 52 week high of LSE:OBI is ÂŁ0.19 and 52 week low is ÂŁ0.08.
When is next earnings date of Ondine Biomedical Inc(LSE:OBI)?
The next earnings date of Ondine Biomedical Inc(LSE:OBI) is 2026-09-25 Est..
Does Ondine Biomedical Inc(LSE:OBI) pay dividends? If so, how much?
Ondine Biomedical Inc(LSE:OBI) does not pay dividend.
Press Release
Articles on Ondine Biomedical Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers